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Abstract
Background Hepatic macrosteatosis (HMS) is prevalent
among high BMI patients, but a lack of validation of non-
invasive measures of liver fat hampers non-alcoholic liver
disease (NAFLD) investigation in general. Recent work
suggests BMI adjusted, non-contrasted computed tomog-
raphy (nc-CT) attenuation data (Hounsﬁeld units) reﬂects
liver fat accumulation in a normal weight population.
However, this and other CT-based HMS studies have only
approximated macrosteatosis (%) histologically, but have
not validated ﬁndings with chemical liver triglyceride (TG)
concentrations (mg/gram protein). Also, all previous CT
based steatosis studies excluded high BMI subjects, whose
habitus may affect properties of the scan. We hypothesized
that in high BMI patients nc-CT attenuation measurements
expressed in Hounsﬁeld units (HU) accurately estimate
liver triglyceride concentrations as well as histological
macrosteatosis.
Methods With informed consent, 15 patients underwent
nc-CT scan of the abdomen prior to weight loss surgery
with intraoperative wedge and core needle liver biopsy.
Mean left lobe nc-CT Hounsﬁeld units (CTL), liver TG
(mg/g Pr), HMS (%), BMI (kg/m
2), liver-spleen index
(CTL/S = hepatic HU/splenic HU), and liver–spleen dif-
ference (CTL-S = hepatic HU - splenic HU) were a priori
outcomes.
Results In15patients(11female)withaBMIof44.4 ± 1.1
(mean ± SEM), CTL/S,C T L-S, and CTL measures were
signiﬁcantly associated with liver TG concentrations (r =
-0.80, P\0.001; r =- 0.80, P\0.001; and r =- 0.71,
P\0.01, respectively; Table 1). Macrosteatosis (%) and
liver triglyceride concentration were positively associated
(r = 0.83; P\0.0001). BMI did not correlate strongly to
liver triglyceride (r = 0.44, P = NS).
Conclusion Estimatesofliverfatobtainedbync-CTscans
(esp. CTL/S,C T L-S) correlate to chemical measurement of
liver triglyceride concentrations, suggesting non-contrasted
CT may be a suitable non-invasive ‘‘gold standard’’ for
hepatic steatosis quantiﬁcation in these patients.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is an emerging
epidemic in the United States and other industrialized
countries [1]. Abnormal fat deposition in the liver has a
signiﬁcant rate of transition to cirrhosis [2] and hepato-
cellular carcinoma [3] and worsens patient response to viral
hepatitis therapy [4]. It is estimated that one-third of
Americans—and 80% of patients undergoing weight-loss
surgery—have fatty liver, and that the sequelae of NAFLD
will eventually supplant hepatitis C virus liver disease as
the number one indication for liver transplant [5]. Unfor-
tunately, fatty liver disease likely has even farther reaching
human health implications. Simple hepatic macrosteatosis
(HMS), deﬁned as macrosteatosis regardless of inﬂamma-
tion, ballooning, or ﬁbrosis, has been linked to insulin
resistance, obesity, hyperlipidemia [6], and atherosclerotic
heart disease in humans [6, 7]. Currently, human clinical
investigation of hepatic steatosis and its response to ther-
apy is limited by dependence upon liver biopsy, an inva-
sive and sometimes unpleasant procedure that carries a
very small risk of serious complication [8].
Several studies have evaluated noninvasive methods for
estimation of HMS, including ultrasound, CT, and MRI [9,
10]. Generally, magnetic resonance imaging techniques
seem to be preferred, especially when it is desirable to
accurately estimate lower levels of hepatic macrosteatosis
and liver triglyceride, since proton NMR is generally
believed to better assess the actual liver triglyceride con-
centration. However, heavily cited MRI studies have
extrapolated triglyceride concentration from animal models
[11] or a small sample of ex vivo liver MRI results col-
lected in a single study [12], so this assumption remains
incompletely tested.
Multiple studies have attempted to correlate computed
tomography (CT) ﬁndings of non-obese subjects to the
degree of HMS demonstrated histologically on hematoxy-
lin and eosin (H&E) stained liver sections with mixed
results [13–15]. Groups have employed an array of atten-
uation indices, usually comparing liver Hounsﬁeld units
(HU) against that of a low adipose internal standard (e.g.,
the spleen, portal vein, left ventricle, etc.). A very recent
report by Liu et al. [16] has proposed an equation to modify
CT attenuation data with subject BMI to better correlate
HU with HMS in patients with [5% macrosteatosis.
However, H&E assisted liver biopsy interpretation of ste-
atosis may only be semiquantitative and susceptible to
interobserver variability [17] and sampling error [18].
Computer and Oil Red O stain have been proposed to
improve precision, but have not been validated chemically
either. As a result, histology as a ‘‘gold standard’’ may
confound the evaluation of a CT scan’s ability to accurately
reﬂect liver fat.
Since no group has correlated CT ﬁndings with actual
laboratory quantiﬁcation of hepatic triglyceride per gram of
liver protein, our aim is to discern whether or not unen-
hanced CT determination of hepatic macrosteatosis based
on image attenuation data (Hounsﬁeld units) is signiﬁ-
cantly correlated to chemical measurement of liver tri-
glyceride (mg/g protein) in high BMI patients, a growing,
unstudied demographic often unsuitable for MRI. Veriﬁed
correlation of these radiologic and laboratory parameters
may facilitate the development of a reliable and non-
invasive standard measurement of liver steatosis for both
clinical and research objectives.
Methods
This workwas an IRB approved prospective, cross sectional
pilot study. From 2009 to 2010, 15 patients scheduled to
undergo elective weight loss surgery (laparoscopic gastric
banding or Roux-en-Y gastric bypass surgery) at Wake
Forest University Baptist Hospital, Winston-Salem, NC,
USA agreed to a preoperative non-contrasted abdominal CT
scan,aswellastheintraoperativecollectionofawedgeliver
biopsy,acoreneedleliverbiopsy,and10 mlofwholeblood.
Previous experiments in obese patients indicated a small
sample size provided sufﬁcient variations in HMS to test
non-contrasted CT’s ability to discern HMS across a broad
spectrum [19]. Patients were excluded for a history of
chronic liver disease other than NAFLD (macrosteatosis in
thesettingofhepaticballooning,inﬂammationorﬁbrosis),a
history of malignancy other than non-melanomatous skin
cancer, an INR greater than 1.8, the need for therapeutic
anticoagulation after surgery, a history of chronic inﬂam-
matory diseases including but not limited to rheumatoid
arthritis, psoriasis, systemic lupus erythematosis, sarcoido-
sis, inﬂammatory bowel disease, greater than or equal to
105 g of ethanol per week, greater than or equal to 45 g in a
given day per week, and refusal to participate.
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For lipid analysis, wedge biopsies from the lateral left
hepatic lobe ranging from 250–500 mg were rinsed with
saline and snap frozen in liquid nitrogen in the operating
room before subsequent storage at -80F. At the time
of analysis, all lipids from minced pieces of liver
(50–100 mg) were extracted in 2:1 chloroform:methanol
overnight [20]. All lipid quantiﬁcation assays were per-
formed on aliquots of the chloroform extract. Measurement
of triglycerides was determined after the addition of Triton-
9100 to solubilize lipids; after removal of the chloroform
by evaporation, lipids were suspended in water and quan-
tiﬁed with enzymatic assays (triglyceride [TG] and cho-
lesterol by Roche Diagnostics and unesteriﬁed cholesterol
by Wako Chemicals USA) [21].
A single intraoperative core needle liver biopsy was
taken from the lateral left lobe of each subject with an
18-gauge spring-loaded MC1820 Bard
TM biopsy device.
These core needle samples were immediately placed in
10% buffered formalin and submitted for histologic eval-
uation of steatosis, necroinﬂammation, ballooning, and
ﬁbrosis by a single expert pathologist using standardized
scoring methods [22, 23]. Hematoxylin and eosin and tri-
chrome slide preparations were performed per center
standards. A semiquantitative measure of HMS was made
by point counting hepatocytes at 4009 optical magniﬁca-
tion. An overlying grid of 35 lm
2 boxes was used to assist
counting. The hepatocytes of ﬁve, non-overlapping ﬁelds
that did not include a portal tract were hand counted,
yielding percentages of hepatocytes as macrosteatotic
(lipid droplets large enough to displace the nucleus and/or
C15 lm), microsteatotic (multiple lipid droplets all smaller
than the nucleus), and normal (no evidence of lipid drop-
lets) [24]. Degrees of HMS were graded according to
convention established by Kleiner et al. [23]: minimal,
\5%; grade 1, 5–33%; grade 2, 33–66%; and grade 3,
[66%. In order to better clinically describe our cohort, the
NASH activity score (NAS) ranging from 0–8 was calcu-
lated on a standardized grading system: HMS (scale of
0–3), lobular inﬂammation (0–3), and hepatocellular bal-
looning (0–2), with higher scores indicating increasing
severity of NASH. NAS scores C5 have been validated as
diagnostic of NASH. Separately, ﬁbrosis was staged 0–4 as
described by Brunt et al. [22].
Computed Tomography
The non-contrasted computed tomography (Lightspeed 16;
GE Medical Systems, Milwaukee, WI) was performed on a
helical scanner set to scan and reconstruct as follows: 0.8 s
rotation time, full 8 detector rows, 2.5 slice thickness,
0.875:1 beam pitch, 8.75 table speed, interval 2.5, SFOV
large, DFOV 35, 140 kV, amperage 350 mA. Images were
reviewed by a single, expert radiologist blinded to biopsy
data who determined hepatic attenuation with Hounsﬁeld
units (HU) in hepatic regions corresponding to the sub-
sequent left liver biopsy site. CT attenuation of three dis-
tinct circular areas was measured in the liver biopsy site
(lateral left lobe) as well as the spleen to generate mean
values. Care was taken to avoid inclusion of visually dis-
tinct vasculature and biliary structures in the regions of
interest.
In addition to simple mean left lobe hepatic attenuation
(CTL), four other indices derived from left lobe CT data
were recorded for comparison to biopsy proven hepatic
macrosteatosis and to chemical measures of hepatic tri-
glyceride concentration. Splenic attenuation was used to
calculate a liver–spleen Index (CTL/S = mean hepatic HU/
mean splenic HU) as well as liver–spleen attenuation dif-
ference (CTL-S = mean hepatic HU - mean splenic HU).
Also, liver attenuation data from the region of interest was
transformed using the equation CTLiu = 47.7 ? 1.48BMI
- 1.18CT Hounsﬁeld units [16]. Liu et al. describe CTLiu
as correlating strongly to macrosteatosis in living liver
donor candidates with HMS [5%. Mean CT attenuation
from the non-biopsied, right lobe (CTr) was also averaged
from three distinct areas and compared to the biopsied
(lateral left) lobe’s chemical, histological, and CT data to
gauge the applicability of ﬁndings throughout the entire
liver.
Statistical Analysis
Data were analyzed using descriptive statistical analysis,
including mean with standard error for continuous vari-
ables and proportions for categorical variables. Compari-
sons between groups were done using chi-square or
Fisher’s exact tests for proportions and the Student’s t tests
for continuous variables. Pearson product-moment corre-
lation coefﬁcients were calculated for continuous variables
to determine strength of the correlation statistic. The sig-
niﬁcance of correlations were calculated from the t-statistic
using the formula t =( vr
2/1-r
2)
 where v = n-2 and
r = correlation coefﬁcient. Log transformations were used
to normalize the distributions of data when needed.
Results
After informed consent, 15 patients (11 females) with a
mean BMI of 44.4 ± 1.1 m/kg
2 (range of 38.3–51.5)
underwent liver biopsy (Table 1). Although the dataset is
small, a wide variation in HMS was observed so that
regression analysis can be appropriately used to compare
Dig Dis Sci (2011) 56:2145–2151 2147
123T
a
b
l
e
1
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
s
u
b
j
e
c
t
s
w
h
o
u
n
d
e
r
w
e
n
t
C
T
s
c
a
n
a
n
d
s
u
b
s
e
q
u
e
n
t
l
i
v
e
r
b
i
o
p
s
y
t
o
e
v
a
l
u
a
t
e
t
h
e
c
o
r
r
e
l
a
t
i
o
n
o
f
u
n
-
e
n
h
a
n
c
e
d
C
T
l
i
v
e
r
a
t
t
e
n
u
a
t
i
o
n
t
o
c
h
e
m
i
c
a
l
l
y
d
e
r
i
v
e
d
l
i
v
e
r
t
r
i
g
l
y
c
e
r
i
d
e
d
a
t
a
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
S
u
b
j
e
c
t
n
u
m
b
e
r
1
2
3
4
5
6
7
8
9
1
0
1
1
1
2
1
3
1
4
1
5
S
e
x
F
e
m
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
M
a
l
e
M
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
M
a
l
e
M
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
F
e
m
a
l
e
A
g
e
(
y
e
a
r
s
)
5
8
3
4
3
0
4
6
3
2
2
1
4
5
6
2
2
7
5
9
5
6
5
4
5
1
4
4
3
2
B
M
I
(
k
g
/
m
2
)
4
8
.
5
3
9
.
4
3
8
.
3
4
2
.
5
4
7
.
0
4
0
.
6
5
1
.
5
4
0
.
5
4
5
.
5
4
6
.
6
4
6
.
7
3
8
.
2
4
9
.
7
4
2
.
1
4
8
.
4
D
i
a
b
e
t
e
s
m
e
l
l
i
t
u
s
N
o
Y
e
s
N
o
N
o
Y
e
s
N
o
N
o
N
o
N
o
Y
e
s
N
o
Y
e
s
N
o
N
o
Y
e
s
L
i
v
e
r
T
G
(
m
g
/
g
P
R
)
2
2
7
1
7
8
5
4
2
,
2
0
3
4
6
5
2
1
7
4
9
4
1
4
0
3
0
2
2
2
2
1
,
0
8
0
4
1
2
7
9
1
9
2
3
2
2
P
l
a
s
m
a
T
G
(
m
g
/
d
l
)
1
2
6
1
9
3
1
6
6
2
0
8
2
2
6
1
8
6
1
5
8
8
9
6
2
1
2
5
2
5
2
5
8
1
5
7
9
2
1
1
8
P
l
a
s
m
a
t
o
t
a
l
c
h
o
l
(
m
g
/
d
l
)
1
8
6
2
1
3
1
6
9
2
1
1
1
6
8
1
2
6
1
7
8
1
5
3
1
0
6
1
,
2
3
0
6
5
1
5
6
1
1
9
1
4
9
1
3
6
P
l
a
s
m
a
L
D
L
C
h
o
l
(
m
g
/
d
l
)
1
4
6
1
5
2
1
1
6
1
7
1
1
2
8
7
4
1
2
5
1
0
9
7
3
9
3
2
7
8
8
6
6
1
1
1
9
5
P
l
a
s
m
a
H
D
L
c
h
o
l
(
m
g
/
d
l
)
2
7
3
5
4
1
2
9
2
0
3
1
3
5
3
9
3
1
2
7
3
7
3
8
4
2
3
2
3
1
P
l
a
s
m
a
V
L
D
L
c
h
o
l
(
m
g
/
d
l
)
1
3
2
6
1
2
1
1
2
1
2
1
1
7
5
2
1
0
1
3
0
1
1
6
1
0
M
a
c
r
o
s
t
e
a
t
o
s
i
s
g
r
a
d
e
(
0
–
4
)
0
0
0
3
1
1
1
1
1
1
2
1
1
0
1
I
n
ﬂ
a
m
m
a
t
o
r
y
g
r
a
d
e
(
0
–
4
)
0
1
1
2
0
0
3
1
0
0
2
2
1
0
1
B
a
l
l
o
o
n
i
n
g
(
0
–
4
)
0
0
0
2
1
0
1
1
0
0
2
1
1
0
2
N
a
s
h
a
c
t
i
v
i
t
y
s
c
o
r
e
(
N
A
S
)
0
1
1
7
2
1
5
3
1
1
6
4
3
0
4
F
i
b
r
o
s
i
s
s
t
a
g
e
(
1
–
4
)
0
0
0
1
0
1
3
0
1
2
3
1
0
0
3
T
G
t
r
i
g
l
y
c
e
r
i
d
e
,
c
h
o
l
c
h
o
l
e
s
t
e
r
o
l
2148 Dig Dis Sci (2011) 56:2145–2151
123liver triglyceride concentration (mg/g liver protein) after
log transformation to both CTL/S (r =- 0.80, P\0.001,
y =- 0.63269?2.5451) (Fig. 1) and CTL-S (r =- 0.80,
P\0.001) (data not shown). The correlations were strong
but statistically signiﬁcant. Histological macrosteatosis (%)
was similarly correlated to the chemical measurement of
liver triglyceride (r = 0.83, P\0.0001) and CTL/S (r =
-0.89, P\0.0001) (Fig. 2a, b). Neither CTL (r =- 0.71,
P\0.01) nor BMI-adjusted nc-CT data as proposed by
Liu et al. (r = 0.80, P = 0.001) reﬂected liver triglyceride
(mg/g liver protein) any more closely than CTL/S.
Mean CT liver–spleen index from the right (non-biop-
sied) liver lobe (CTrL/S) also correlated strongly to log
transformed liver triglyceride (r =- 0.79, P\0.01) and
HMS (r =- 0.88, P\0.001), while mean biopsied left
liver lobe attenuation (CTL) and non-biopsied liver atten-
uation (CTr) was even more similar (r = 0.96, P\0.0001,
n = 15). BMI was only marginally and nonsigniﬁcantly
correlated with liver triglyceride concentration, the deﬁni-
tive measure of hepatic fat (r = 0.44, P[0.05) (Fig. 3).
Seventy-three percent of subjects demonstrated at least
mild HMS by surgical pathology evaluation (n = 11).
Sixty percent and 53% of participants were found to have
necroinﬂammation (n = 9) and/or at least stage 1 ﬁbrosis
(n = 11), respectively. Four biopsies revealed stage 3
ﬁbrosis, and no subjects had cirrhosis. Mean percentage of
histological macrosteatosis was 27 ± 5.9%. Three subjects
met the predetermined criteria for steatohepatitis with a
NASH activity score (NAS) C5. Individual NAS ranged
from 0–6. The liver triglyceride concentrations distributed
widely from 54–2,203 mg/g of liver protein with a mean
(±sem) value of 480 ± 142 mg/g Pr (n = 15).
Discussion
This study has conﬁrmed the utility of using nc-CT
scanning to noninvasively evaluate the extent of liver
Fig. 1 Correlation of liver spleen index to liver triglyceride. Liver
spleen index [liver attenuation (HU)/splenic attenuation (HU)]
correlates strongly with chemical measurement of liver triglyceride
(mg/gPR) (r =- 0.80, P\0.001, n = 15)
Fig. 2 Correlation of liver macrosteatosis (%) to liver triglyceride
(a) and liver spleen index (CTL/S)( b). Histological macrosteatosis
(HMS) correlates strongly with chemical measurement of liver
triglyceride (mg/g PR) (r = 0.83, P\0.0001, n = 15) and CTL/S
(r =- 0.89, P\0.0001, n = 15)
Fig. 3 Correlation of BMI to liver triglyceride. Subject BMI (kg/m
2)
does not correlate signiﬁcantly with liver triglyceride (mg/g protein)
(r = 0.44, P[0.05, n = 15)
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BMI patients, a growing population previously not studied
with CT. The Hounsﬁeld units obtained from the CT scan
were signiﬁcantly and directly correlated to the chemical
assessment of hepatic triglyceride and to a standardized
histologic estimation of HMS. While the number of
patients examined in this study was small, the correlation
extended across a quite wide range of liver triglyceride
concentrations (Fig. 1) so that the measurements are rea-
sonably robust and provide good estimates of triglyceride
concentrations across the range of minimal to very high
macrosteatosis. CT assessment of hepatic steatosis in ear-
lier studies was criticized on the basis that the modality
provided limited accuracy to estimate hepatic fat concen-
tration accurately where this was low [15]. However, such
criticism cannot be leveled at our dataset.
A strength of this study is that it is the ﬁrst direct
comparison of CT attenuation to chemical hepatic tri-
glyceride concentrations of which we are aware. Multiple
groups have reported that non-contrasted hepatic CT ﬁnd-
ings signiﬁcantly correlate to HMS estimated by a single
observer [14–16]. When reviewed together, these studies
provide the impression that nc-CT scan may be of value in
measuring liver fat above 30% HMS or when adjusted for
individual BMI. However, all of these studies rely on the
assumption that estimation of HMS from a core liver
biopsy accurately represents in vivo liver triglyceride
concentration. Until now this assumption has not been
tested in humans.
Additionally, CT data of the non-biopsied right liver
lobe (CTr) correlated strongly to liver TG, HMS, and CT
attenuation of the biopsied lobe. In the context of previ-
ously published strong correlations in HMS between paired
liver biopsies, such ﬁndings suggest our liver fat measures
(HMS, TG, CT) apply broadly to most of the liver, thereby
allaying a common concern in non-invasive hepatic diag-
nostic studies [18]. Lastly, this work chemically validates
the use of a CT ‘‘Liver Spleen Index’’ (or ratio) to control
for an individual subjects’ scanning characteristics.
Our study has important limitations including small
cohort size and the inclusion of only very high BMI sub-
jects. However, in designing our study we believe that the
existing data supporting nc-CT and our knowledge of the
wide spectrum of HMS within a bariatric surgery cohort
justiﬁed a small sample size both from a statistical and an
ethical standpoint, not least given the potential risks asso-
ciated with wedge liver biopsies and radiation exposure for
non-clinical purposes. Also, we must acknowledge that a
liver biopsy still remains essential for the determination of
histological features of hepatocyte ballooning, inﬂamma-
tion and ﬁbrosis that are of considerable importance in the
full characterization of fatty liver disease. Finally, we are
aware that the lifetime risk of medical radiation exposure is
an emerging concern for clinicians [25]. The radiation
exposure of the CT measures used here is relatively mod-
est, however, and is conﬁned to an abdominal region not
involving the entire body, so the risk for such a procedure
remains low.
In summary, we believe the novel observation that
nc-CT hepatic attenuation closely reﬂects both hepatic
macrosteatosis and chemically measured liver triglyceride
across a wide range of steatosis (54–2,203 mg/g Pr),
eliminating interobserver variability, offers many interest-
ing possibilities for the care of liver patients and liver
donors. A convenient, validated measure of HMS alone
would be a boon to clinicians and researchers, attempting
to unravel the complex interplay between liver lipid burden
and human metabolism as a whole. Based on our results,
unenhanced computed tomography may represent liver
triglyceride accurately enough to ﬁll such a role. Conﬁr-
mation of our results by a larger study would ultimately
serve to elucidate the risk and beneﬁts of this proposed use
of computed tomography in obese and non-obese patients
alike.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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